Glycogen synthase kinase 3: A key regulator of cellular fate

被引:328
作者
Forde, J. E. [1 ]
Dale, T. C. [1 ]
机构
[1] Cardiff Sch Biosci, Cardiff CF10 3US, Wales
基金
英国生物技术与生命科学研究理事会;
关键词
glycogen synthase kinase-3 (GSK-3); mechanism of action; inhibitors; signalling; disease; kinase; regulation;
D O I
10.1007/s00018-007-7045-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified as a key regulator of insulin-dependent glycogen synthesis. GSK-3 was subsequently shown to function in a wide range of cellular processes including differentiation, growth, motility and apoptosis. Aberrant regulation of GSK-3 has been implicated in a range of human pathologies including Alzheimer's disease, non-insulin dependent diabetes mellitus ( NIDDM) and cancer. As a consequence, the regulation of GSK-3 and the therapeutic potential of GSK-3 inhibitors have become key areas of investigation. This review will focus on the mechanisms of GSK-3 regulation, with emphasis on modulation by upstream signals, control of substrate specificity and GSK-3 localisation. The details of these mechanisms will be discussed in the context of specific signalling pathways.
引用
收藏
页码:1930 / 1944
页数:15
相关论文
共 139 条
[81]   Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent [J].
Meijer, L ;
Thunnissen, AMWH ;
White, AW ;
Garnier, M ;
Nikolic, M ;
Tsai, LH ;
Walter, J ;
Cleverley, KE ;
Salinas, PC ;
Wu, YZ ;
Biernat, J ;
Mandelkow, EM ;
Kim, SH ;
Pettit, GR .
CHEMISTRY & BIOLOGY, 2000, 7 (01) :51-63
[82]   GSK-3-selective inhibitors derived from Tyrian purple indirubins [J].
Meijer, L ;
Skaltsounis, AL ;
Magiatis, P ;
Polychronopoulos, P ;
Knockaert, M ;
Leost, M ;
Ryan, XZP ;
Vonica, CA ;
Brivanlou, A ;
Dajani, R ;
Crovace, C ;
Tarricone, C ;
Musacchio, A ;
Roe, SM ;
Pearl, L ;
Greengard, P .
CHEMISTRY & BIOLOGY, 2003, 10 (12) :1255-1266
[83]   Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects [J].
Mettey, Y ;
Gompel, M ;
Thomas, V ;
Garnier, M ;
Leost, M ;
Ceballos-Picot, I ;
Noble, M ;
Endicott, J ;
Vierfond, JM ;
Meijer, L .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (02) :222-236
[84]   Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β [J].
Mukai, F ;
Ishiguro, K ;
Sano, Y ;
Fujita, SC .
JOURNAL OF NEUROCHEMISTRY, 2002, 81 (05) :1073-1083
[85]   Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc [J].
Neal, JW ;
Clipstone, NA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (05) :3666-3673
[86]  
NIKOLAKAKI E, 1993, ONCOGENE, V8, P833
[87]   Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface [J].
Nusse, R .
DEVELOPMENT, 2003, 130 (22) :5297-5305
[88]   Hedgehog stimulates maturation of Cubitus interruptus into a labile transcriptional activator [J].
Ohlmeyer, JT ;
Kalderon, D .
NATURE, 1998, 396 (6713) :749-753
[89]   R-Ras controls axon specification upstream of glycogen synthase kinase-3β through integrin-linked kinase [J].
Oinuma, Izumi ;
Katoh, Hironori ;
Negishi, Manabu .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (01) :303-318
[90]   Pyrazolo[3,4-b]quinoxalines.: A new class of cyclin-dependent kinases inhibitors [J].
Ortega, MA ;
Montoya, ME ;
Zarranz, B ;
Jaso, A ;
Aldana, I ;
Leclerc, S ;
Meijer, L ;
Monge, A .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (07) :2177-2184